| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2003;41:925.)
© 2003 American Heart Association, Inc.
Scientific Contributions |
From the Division of Medicine and Therapeutics, University of Leicester, Leicester, England.
Correspondence to Prof L.L. Ng, University of Leicester, Division of Medicine and Therapeutics, Level 4, Clinical Sciences Bldg, Leicester Royal Infirmary, Leicester LE2 7LX UK. E-mail lln1{at}le.ac.uk
| Abstract |
|---|
|
|
|---|
Key Words: preeclampsia oxidative stress lymphocytes genetics signal transduction
| Introduction |
|---|
|
|
|---|
The mechanisms leading to increased ROS production is unclear. In support of plasma factors being implicated in neutrophil activation, preeclamptic serum potentiates the production of ROS in nonpregnant neutrophils, whereas serum from normal or nonpregnant women does not.2 However, other studies have been unable to identify any evidence of such a factor in serum from preeclamptic women.7 Alternatively, a genetic predisposition may be implicated in this neutrophil activation and subsequent ROS production.
The NADPH oxidase enzyme is an important source of ROS and consists of membrane-bound flavocytochrome b as well as cytosolic components.8 NADPH oxidase is activated by a variety of agents including n-formyl-Met-Leu-Phe (fMLP) and phorbol-12-myristate-13-acetate (PMA). Regulation of this process is mediated by specific signal transduction pathways that initiate the translocation of several cytosolic proteins to the membrane, where the active NADPH oxidase is formed.8 The signal transduction pathways controlling NADPH oxidase activation are still poorly documented. There are protein kinase C (PKC) dependent and independent pathways of activation that are either calcium dependent or independent.9,10 There is now increasing evidence implicating the role of tyrosine phosphorylation as an integral part of the signaling pathway as tyrosine phosphorylation of several polypeptides is increased in neutrophils stimulated with fMLP and PMA.11
Like neutrophils, Epstein-Barr virus (EBV)-immortalized lymphoblasts express all constituents of the NADPH oxidase complex necessary to generate ROS and may therefore be a useful model for study of NADPH oxidase activity and subsequent production of ROS in preeclampsia.12 Consequently, EBV-immortalized lymphoblasts may provide a robust and stable cell line model free of the in vivo environmental influences.
The current study aimed to examine NADPH oxidasemediated ROS production in EBV-immortalized lymphoblasts from both third-trimester preeclamptic and postpartum preeclamptic women and their respective control subjects. This may be a first step toward the identification of genetic influences on NADPH oxidasemediated ROS production in preeclampsia, since cells are removed from the influences of plasma factors in vivo. Furthermore, we examined the basis for differences or upregulation in the signal transduction pathways upstream of NADPH oxidasemediated ROS production.
| Methods |
|---|
|
|
|---|
| Materials |
|---|
|
|
|---|
Lymphoblast Culture
Immortalized lymphoblast cell lines were established as described previously.14 Cell lines were fed every 2 to 3 days with RPMI supplemented with 10% FCS, 2 mmol/L glutamine, penicillin (200 U/L), and streptomycin (0.2 mg/L).
Luminol-Derived Chemiluminescence
Measurement of ROS production was performed in buffer A consisting of (in mmol/L) NaCl 140, KCl 5, MgSO4 0.8, CaCl2 1.8, glucose 5, and HEPES 15, pH 7.4. ROS production was measured according to the method of Allen and Loose.15 Briefly, 400 000 neutrophils were washed in luminescence medium containing 5 µmol/L luminol (5-amino-2,3-dihydro 1,4-phthalazinedione) and 6 U/mL HRP. The cells were then resuspended in 500 µL of luminescence solution, and the baseline was measured in a thermostatically controlled EG&G Berthold LB953 tube luminometer set at 37°C. The respiratory burst was then stimulated with the use of 1 µmol/L PMA. The response was recorded over a period of 30 minutes. The luminescence was measured as the light emission of a single sample over a time period. The area under the curve (AUC) was taken to represent ROS when the oxidase was stimulated. Simpsons rule was used to calculate the AUC in relative light unit seconds (RLU.sec). Coefficients of variation for the same individual on different days for PMA-stimulated luminol-derived chemiluminescence (LDCL) was 12.4%.
Dihydrorhodamine-123 Fluorescence
ROS was also determined with the use of fluorescence of rhodamine-123 produced from oxidation of dihydrorhodamine-123, as previously described.16 Briefly, 105 cells were incubated at 37°C in 200 µL buffer A within ELISA plate wells, and dihydrorhodamine-123 (final concentration, 1 µmol/L) was added. Fluorescence was measured on a plate reader with excitation set at 505 nm (emission, 534 nm). Cells were stimulated with 1 µmol/L PMA and incubated for 60 minutes at 37°C. The fluorescence of rhodamine-123 was determined after subtraction of signals from wells without PMA addition to correct for auto-oxidation of dihydrorhodamine-123.16
NADPH Oxidase Protein Abundance
Lymphoblast NADPH oxidase protein abundance was analyzed with the use of Western blotting.14,17 Fifty micrograms of protein extract was resolved on SDS-polyacrylamide gels (between 7.5 and 15%) and transferred to supported nitrocellulose. Proteins were detected by incubating blots with 1 µg/mL of p22, p47, p67, or gp91 antibody in 5% Marvel in PBS0.1% Tween-20 for 1 hour, as previously described.17 HRP-linked donkey anti-rabbit IgG (1:1500) was added to blots for 1 hour. The bands of interest were visualized with the use of enhanced chemiluminescence methodology.14,17 Densities of bands were scanned with the use of a Bio-Rad densitometer.
Assessment of Signaling Pathways in NADPH Oxidase Activation
Lymphoblasts were incubated in buffer A with various inhibitors of signal transduction pathways to elucidate control mechanisms of enhanced NADPH oxidase activity. A table that is available as an online supplement (at http://www.hypertensionaha.org) illustrates the inhibitors, their concentrations, duration of incubation, and effects. Inhibitors were added and incubated at 37°C for the stated times before assaying the cells for LDCL as above.
Statistical Analysis
Differences in lymphoblast LDCL and rhodamine-123 fluorescence were tested with the use of the Univariate General Linear Model (GLM) procedure in SPSS, Version 11. Other comparisons were performed using the Student t test. Box-and-whisker plots were produced, with median and boxes representing the interquartile range. All data were tested for normality by means of the Anderson-Darling test. In the protein abundance experiments, all data were normalized to a mean value of 1.0 in the control group. Statistical analysis was then performed accordingly. Probability values <0.05 were considered significant.
| Results |
|---|
|
|
|---|
90% (P<0.001, Figure 1C). The luminol response was
70% inhibited by catalase (P<0.001, Figure 1C). This suggested that luminol was not completely specific for hydrogen peroxide and measured other reactive oxygen species in addition to hydrogen peroxide.
|
|
These LDCL results were confirmed with a different assay for ROS, fluorescence of rhodamine-123, which measures both superoxide and hydrogen peroxide.16 With the use of the Univariate GLM procedure, there was again no significant effect of pregnancy status on lymphoblast ROS production (F statistic, 0.218; P=N/S). However, lymphoblasts from preeclamptic women had higher ROS production than normal women (Figure 1D; F statistic, 27.55; P<0.001).
We assessed whether any differences existed in the abundance of the membrane bound and cytosolic subcomponents of the oxidase enzyme. Figure 2A illustrates typical Western blots probed with antibodies against the different phox components. Figure 2B illustrates the results of the densitometric analysis of the blots. Values were normalized to a mean of 1.0 in the control group. No significant differences were seen in abundance of any of the phox components of the oxidase enzyme.
|
These blots were obtained from unstimulated cells. We also investigated the effect of PMA stimulation (1 µmol/L) on abundance of phox subunits before and after 30 minutes of stimulation at 37°C in buffer A. All data on Western blots were normalized to 1 in the control group (n=8). There was no significant change in abundance of any of the subunits investigated (densitometry for control resting cells, PMA-stimulated control cells, preeclamptic resting cells, PMA-stimulated preeclamptic cells, respectively for the different subunits:p47 phox: 1.00±0.24, 1.14±0.11, 1.19±0.24, 1.33±0.11; p67 phox: 1.00±0.16, 1.11±0.22, 1.04±0.16, 1.23±0.23; p22 phox: 1.00±0.23, 1.18±0.24, 1.04±0.23, 1.30±0.24; P=N/S for all comparisons using the repeated-measures GLM procedure).
Because the higher ROS production in cell lines derived from preeclamptic patients was not due to differences in phox component abundance, we investigated the upstream signaling pathways involved in NADPH oxidase regulation. Inhibitors and concentrations used are reported in the table published as an online supplement. Ro318220, a PKC inhibitor, inhibited NADPH oxidasemediated ROS production completely after stimulation with PMA in both preeclamptic (10.03±1.99 versus 0.001±0.0007 107 RLU.sec) and normotensive control subject (3.97±1.56 versus 0.0007±0.0002 107 RLU.sec) cell lines. The effect of genistein on inhibition of NADPH oxidase activation with PMA is illustrated in Figure 3. Genistein inhibited NADPH oxidase mediated ROS production in both the preeclamptic (10.30±2.82 versus 4.05±1.24 107 RLU.sec) and normotensive control group (2.77±1.28 versus 0.77±0.36 107 RLU.sec). The difference between mean uninhibited and inhibited ROS values was only significant in the preeclamptic group using a paired Students t test (P=0.020). The effect of tyrphostin A20 on inhibition of NADPH oxidase activation with PMA is illustrated in Figure 4. Mean uninhibited (control) values were compared with mean inhibited values in both groups by means of a paired Students t test. Tyrphostin A20 inhibited NADPH oxidase activation in both the preeclamptic (8.92±2.59 versus 5.875±2.257 107 RLU.sec) and normotensive (2.03±1.10 versus 0.604±0.38 107 RLU.sec) control groups. The difference between mean uninhibited and inhibited ROS values was only significant in the preeclamptic group (P=0.007). The effect of MEK, p38 MAPK, and phosphatidylinositol-3-kinase inhibitors (PD98059, SB203580, and wortmannin respectively) on NADPH oxidase activation was analyzed. None had significant inhibitory effects on PMA-stimulated ROS production in either preeclamptic or normotensive cell lines (data not shown).
|
|
| Discussion |
|---|
|
|
|---|
EBV-immortalized lymphoblasts were used to examine the role of NADPH oxidase activity and ROS production as an intermediate phenotype in preeclampsia. Luminol was incorporated as the chemiluminogenic probe with which to measure the response because lucigenin responses were not sensitive enough to measure the ROS produced. Responses were corroborated with another ROS-sensitive probe, rhodamine-123 fluorescence. Lymphoblasts do not have fMLP receptors, so PMA was chosen as the agonist.23 This study revealed increased agonist-induced ROS production in both preeclamptic and postpartum preeclamptic lymphoblast lines compared with respective normal controls. Pregnancy had no significant effect on lymphoblast ROS production measured by 2 different techniques. This increased sensitivity may have been influenced by genetic factors, since culture of these lines in vitro eliminates the influence of environmental (plasma) factors. Such experiments could not be performed on the NADPH oxidase of isolated neutrophils because they do not remain viable with prolonged culture. In addition, the presence of this increased sensitivity of the NADPH oxidase, independent of any effect of pregnancy status, is suggestive of a genetic influence, since preeclampsia as a clinical condition rapidly regresses after parturition.
There is evidence in the literature to suggest that preeclamptic cells are "primed" by some factor in the plasma, rendering them more sensitive to agonist stimulation with increased ROS production.24 TNF-
, platelet-activating factor, and syncytiotrophoblast microvesicles are among the factors that may contribute.7,25,26 However, the results presented do not favor this hypothesis because the increased sensitivity persisted in EBV-immortalized lymphoblasts when the environmental (plasma) factors were removed. This suggests that women with preeclampsia may be genetically predisposed to have an NADPH oxidase that is more sensitive to agonist stimulation, similar to that of a "primed" cell. It is therefore postulated that the preeclamptic environment may contain the actual stimulus for this activation, but a predisposition exists. A recent study by Barden et al27 supports this theory by suggesting that there may be some underlying genetic predisposition to increased oxidative stress. Their study does not suggest that a stable circulating factor causes cell activation in preeclampsia. However, they showed that lipid peroxidation is indeed elevated before and after delivery in women with preeclampsia.27
Underlying mechanisms for this increased ROS production are unclear. There is an increased abundance of p22 phox in hypertensive lymphoblasts, which may account for the increased ROS production on PMA stimulation.17 However, we found no differences in any of the phox subunits between preeclamptic and normal lines. None of our patients had a family history of hypertension. Upstream signaling pathways were examined to elucidate upregulation that may have contributed to this increased ROS production. Using the inhibitor Ro318220, we confirmed that PMA-mediated stimulation of the respiratory burst was dependent on PKC activation. In contrast to findings in neutrophils,28 p38 MAPK was not implicated in the signal transduction pathways leading to NADPH oxidase activation in these lymphoblasts, since the inhibitor SB203580 did not have any effect on ROS production in either group of cell lines. The minor role of ERK 1/2 in PMA-stimulated activation as the respiratory burst was also confirmed in the current study, since the MEK inhibitor PD98059 had no significant effect on PMA-stimulated ROS production of lymphoblasts.10 A role for phosphatidylinositol-3-kinase was also excluded because the inhibitor wortmannin had no effect on the response. However, both genistein and tyrphostin, inhibitors of tyrosine kinases, partially blocked the production of ROS on activation with PMA in both sets of cell lines but to a significant degree only in the preeclamptic group. These findings suggested the importance of a tyrosine kinase regulatory pathway involved in enhanced PMA-stimulated NADPH oxidase activity associated with the preeclamptic phenotype. Similar findings have been reported in the priming of neutrophils by TNF-
. Utsumi et al29 suggested that tyrosine kinase activity was involved in the "priming-linked" generation of superoxide. However, the role for a tyrosine phosphorylation step in the increased sensitivity and activation of the NADPH oxidase of cells from preeclamptic patients remains elusive. Tyrosine phosphorylation of several polypeptides is increased in neutrophils stimulated with fMLP and PMA.11,30
In conclusion, this is the first report of an increased sensitivity of the NADPH oxidase enzyme to stimulation with PMA in preeclampsia with EBV-immortalized lymphoblasts used as models. Results were confirmed by using 2 different ROS measuring techniques. This increased sensitivity persisted in the postpartum preeclamptic cell lines and may have been due to genetic factors, since environmental (plasma) factors were removed. The increased sensitivity may contribute to the neutrophil activation in preeclampsia through its ability to produce substantially more ROS on agonist stimulation. The enhancement of ROS generation may be important in mediating the endothelial dysfunction seen in preeclampsia. In addition, tyrosine kinasedependent mechanisms may be implicated in control of the NADPH oxidaseassociated increased ROS production with preeclampsia.
Perspectives
There is an increased sensitivity of NADPH oxidase enzyme on agonist stimulation with PMA in EBV-immortalized lymphoblasts isolated from preeclamptic and postpartum preeclamptic women, a novel cell culture model for further investigation of this preeclamptic intermediate phenotype. This phenomenon is tyrosine kinase dependent, and its persistence in cultured cells suggests a genetic origin. However, some caution must be exercised when generalizing these findings to the majority of patients with preeclampsia. Critical areas for further investigation concern the identification of low abundancespecific proteins that could be tyrosine phosphorylated, the involvement of these proteins in the signal transduction pathways in preeclampsia, and their investigation as targets for pharmacological manipulation. Moreover, the predictive value of such an intermediate phenotype could be examined in the future by prospective clinical studies in pregnancy.
| Acknowledgments |
|---|
Received August 19, 2002; first decision September 13, 2002; accepted February 6, 2003.
| References |
|---|
|
|
|---|
2. Tsukimori K, Maeda H, Ishida K, Nagata H, Koyanagi T, Nakano H. The superoxide generation of neutrophils in normal and preeclamptic pregnancies. Obstet Gynecol. 1993; 81: 536540.[Medline] [Order article via Infotrieve]
3. Crocker IP, Wellings RP, Fletcher J, Baker PN. Neutrophil function in women with preeclampsia. Br J Obstet Gynaecol. 1999; 106: 822828.[Medline] [Order article via Infotrieve]
4. Dekker GA, Kraayenbrink AA, Zeeman GG, van Kamp GJ. Increased plasma levels of the novel vasoconstrictor peptide endothelin in severe preeclampsia. Eur J Obstet Gynecol Reprod Biol. 1991; 40: 215220.[CrossRef][Medline] [Order article via Infotrieve]
5. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986; 320: 454456.[CrossRef][Medline] [Order article via Infotrieve]
6. Davidge ST. Oxidative stress and altered endothelial cell function in preeclampsia. Semin Reprod Endocrinol. 1998; 16: 6573.[Medline] [Order article via Infotrieve]
7. Clark CJ, Boswell F, Greer IA, Lyall F. Treatment of endothelial cells with serum from women with preeclampsia: effect on neutrophil adhesion. J Soc Gynecol Investig. 1997; 4: 2733.[Medline] [Order article via Infotrieve]
8. Babior BM, Lambeth JD, Nauseef W. The neutrophil NADPH oxidase. Arch Biochem Biophys. 2002; 397: 342344.[CrossRef][Medline] [Order article via Infotrieve]
9. Della Bianca V, Grzeskowiak M, Dusi S, Rossi F. Transmembrane signaling pathways involved in phagocytosis and associated activation of NADPH oxidase mediated by Fc gamma Rs in human neutrophils. J Leukoc Biol. 1993; 53: 427438.[Abstract]
10. Dewas C, Fay M, Gougerot-Pocidalo MA, El-Benna J. The mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway is involved in formyl-methionyl-leucyl-phenylalanine- induced p47phox phosphorylation in human neutrophils. J Immunol. 2000; 165: 52385244.
11. Huang CK, Bonak V, Laramee GR, Casnellie JE. Protein tyrosine phosphorylation in rabbit peritoneal neutrophils. Biochem J. 1990; 269: 431436.[Medline] [Order article via Infotrieve]
12. Jones OTG, Wood JD. Oxidant production by human B lymphocytes: detection of activity and identification of components involved. Methods. 1996; 9: 619627.[CrossRef][Medline] [Order article via Infotrieve]
13. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol. 1988; 158: 892898.[Medline] [Order article via Infotrieve]
14. Ng LL, Sweeney FP, Siczkowski M, Davies JE, Quinn PA, Krolewski B, Krolewski AS. Na(+)-H+ antiporter phenotype, abundance, and phosphorylation of immortalized lymphoblasts from humans with hypertension. Hypertension. 1995; 25: 971977.
15. Allen RC, Loose LD. Phagocytic activation of a luminol-dependent chemiluminescence in rabbit alveolar and peritoneal macrophages. Biochem Biophys Res Commun. 1976; 69: 245252.[CrossRef][Medline] [Order article via Infotrieve]
16. Bueb JL, Gallois A, Schneider JC, Parini JP, Tschirhart E. A double-labelling fluorescent assay for concomitant measurements of [Ca2+]i and O2. production in human macrophages. Biochim Biophys Acta. 1995; 1244: 7984.[Medline] [Order article via Infotrieve]
17. Pettit AI, Wong RK, Lee V, Jennings S, Quinn PA, Ng LL. Increased free radical production in hypertension due to increased expression of the NADPH oxidase subunit p22(phox) in lymphoblast cell lines. J Hypertens. 2002; 20: 677683.[CrossRef][Medline] [Order article via Infotrieve]
18. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia. an endothelial cell disorder. Am J Obstet Gynecol. 1989; 161: 12001204.[Medline] [Order article via Infotrieve]
19. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol. 1999; 31: 5160.[CrossRef][Medline] [Order article via Infotrieve]
20. Cosentino F, Sill JC, Katusic ZS. Role of superoxide anions in the mediation of endothelium-dependent contractions. Hypertension. 1994; 23: 229235.
21. Liu HS, Chu TY, Yu MH, Chang YK, Ko CS, Chao CF. Thromboxane and prostacyclin in maternal and fetal circulation in pre-eclampsia. Int J Gynaecol Obstet. 1998; 63: 16.[CrossRef][Medline] [Order article via Infotrieve]
22. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys. 1991; 288: 481487.[CrossRef][Medline] [Order article via Infotrieve]
23. Volkman DJ, Buescher ES, Gallin JI, Fauci AS. B cell lines as models for inherited phagocytic diseases: abnormal superoxide generation in chronic granulomatous disease and giant granules in Chediak-Higashi syndrome. J Immunol. 1984; 133: 30063009.[Abstract]
24. von Dadelszen P, Wilkins T, Redman CW. Maternal peripheral blood leukocytes in normal and pre-eclamptic pregnancies. Br J Obstet Gynaecol. 1999; 106: 576581.[Medline] [Order article via Infotrieve]
25. Wang Y, Gu Y, Philibert L, Lucas MJ. Neutrophil activation induced by placental factors in normal and pre- eclamptic pregnancies in vitro. Placenta. 2001; 22: 560565.[CrossRef][Medline] [Order article via Infotrieve]
26. Lal AS, Clifton AD, Rouse J, Segal AW, Cohen P. Activation of the neutrophil NADPH oxidase is inhibited by SB 203580, a specific inhibitor of SAPK2/p38. Biochem Biophys Res Commun. 1999; 259: 465470.[CrossRef][Medline] [Order article via Infotrieve]
27. Barden A, Ritchie J, Walters B, Michael C, Rivera J, Mori T, Croft K, Beilin L. Study of plasma factors associated with neutrophil activation and lipid peroxidation in preeclampsia. Hypertension. 2001; 38: 803808.
28. Lal AS, Clifton AD, Rouse J, Segal AW, Cohen P. Activation of the neutrophil NADPH oxidase is inhibited by SB 203580, a specific inhibitor of SAPK2/p38. Biochem Biophys Res Commun. 1999; 259: 465470.[CrossRef][Medline] [Order article via Infotrieve]
29. Utsumi T, Klostergaard J, Akimaru K, Edashige K, Sato EF, Utsumi K. Modulation of TNF-alpha-priming and stimulation-dependent superoxide generation in human neutrophils by protein kinase inhibitors. Arch Biochem Biophys. 1992; 294: 271278.[CrossRef][Medline] [Order article via Infotrieve]
30. Berkow RL, Dodson RW. Tyrosine-specific protein phosphorylation during activation of human neutrophils. Blood. 1990; 75: 24452452.
This article has been cited by other articles:
![]() |
K. Bedard and K.-H. Krause The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology Physiol Rev, January 1, 2007; 87(1): 245 - 313. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tsukimori, K. Fukushima, A. Tsushima, and H. Nakano Generation of Reactive Oxygen Species by Neutrophils and Endothelial Cell Injury in Normal and Preeclamptic Pregnancies Hypertension, October 1, 2005; 46(4): 696 - 700. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. M. Raijmakers, R. Dechend, and L. Poston Oxidative Stress and Preeclampsia: Rationale for Antioxidant Clinical Trials Hypertension, October 1, 2004; 44(4): 374 - 380. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |